SHTG Daily Digest — Weiss Lab

A thin cycle on both fronts — the lipid literature offered only next-tier work (an ANGPTL3 base-editing delivery study, an APOC3 variant association in Indian MASLD, and two clinical-care papers on hypertriglyceridemia), and the industry side produced no new SHTG news, with the only fresh item being Ionis's partnered antisense drug sefaxersen hitting its Phase 3 interim endpoint in IgA nephropathy with Roche.

It's a thin cycle on both fronts — the only notable lipid-biology paper this week is a new CRISPR rabbit model of APOA5-driven hypertriglyceridemia, and the SHTG-relevant industry press was quiet, with searches turning up only stories already covered in recent episodes.

A quiet cycle on both fronts — the lipid literature offered only next-tier evidence (CRISPR/base-editing for ANGPTL3, plasma exchange for SHTG crises, and an erythritol-apoC-III diet link), and the industry side had no new Arrowhead/Alnylam/Ionis news beyond last cycle's already-covered Novartis/Ionis pelacarsen failure.

A new JACC: Basic to Translational Science analysis shows ApoC-III inhibition with olezarsen strips triglycerides and cholesterol out of Lp(a) particles without lowering Lp(a) mass itself, while two case reports underline how hard SHTG still is to diagnose and treat at the bedside — and it was a quiet week for Arrowhead, Alnylam, and Ionis in the trade press.

A quiet cycle on both fronts — PubMed's top-tier journals produced zero SHTG/ANGPTL/APOC3/LPL hits this week (next-best-tier picks below cover ANGPTL3 inhibition, lipodystrophy genetics, and LPL biochemistry), and none of the tracked trade outlets published fresh news on SHTG, Arrowhead, Alnylam, or Ionis in the last five days.

No top-tier journal papers cleared the bar this cycle, but next-tier literature offered genetics-to-therapy signal on FCS (a novel APOA5 variant and an ApoC-II case series) alongside two olezarsen/zodasiran commentary pieces, while the industry side was quiet — everything found in the 5-day window on Arrowhead, Alnylam, or Ionis's lipid programs had already been covered in the prior cycle.

It's a quiet cycle on both fronts — no top-tier-journal lipid papers cleared the bar, but the biggest industry story is a jolt: Novartis and Ionis's Lp(a)-lowering drug pelacarsen just failed its pivotal cardiovascular outcomes trial, raising hard questions for the whole class of RNA-targeting lipid therapies (including the APOC3/ANGPTL3 programs this show tracks).

A quiet cycle on both fronts — no top-tier lipid papers cleared the bar in PubMed this week, and no genuinely new SHTG/Arrowhead/Alnylam/Ionis industry stories broke in the last 5 days beyond what's already been covered (Tryngolza's sHTG approval and Arrowhead's ESC '26 plozasiran data remain the dominant recent storylines).

This is a quiet, largely repeat cycle — the CTX310 (ANGPTL3 base-editing) durability letter and the Arrowhead-vs-Ionis ESC Congress safety showdown that drove the last digest remain the dominant SHTG stories, with nothing genuinely new clearing the bar on either the science or industry side since two days ago.

ESC Congress in Munich delivered the payoff this cycle predicted last time — CRISPR Therapeutics published one-year durability data for its ANGPTL3 base-editing candidate CTX310 in NEJM, while Arrowhead used the same meeting to lay out a case that plozasiran (Redemplo) is at least as good as, and possibly safer than, Ionis's Tryngolza in severe hypertriglyceridemia.

No new top-tier lipid papers broke this cycle, but a strong human ANGPTL3-deficiency kinetics study and a novel TREM2–APOC3 mechanism paper stood out on the science side, while the industry side was quiet on new sHTG-specific news in the last five days — the main thing to watch is ESC Congress in Munich, though this year it's Alnylam's amyloid-cardiomyopathy franchise, not its lipid pipeline, in the spotlight.

No top-tier-journal SHTG papers landed this cycle, but a broadened PubMed pull surfaced two drug-focused reviews on plozasiran and olezarsen plus a Korean GWAS turning up a novel ANGPTL3 variant, while the industry side stayed quiet with nothing new in the 5-day window from Ionis, Arrowhead, or Alnylam.

No top-tier journal papers on SHTG/ANGPTL/APOC3/LPL cleared the bar this cycle (next-best-tier picks below on ANGPTL3 inhibition and APOC3-targeted siRNA are still worth a read), and it's a quiet week for Arrowhead/Alnylam/Ionis press coverage ahead of the SHASTA-3/4 late-breaker at ESC on August 30.

No top-tier trial readouts this cycle, but the science side keeps chipping at the APOC3/ANGPTL3/ANGPTL4/LPL mechanism (postprandial handling, CKD dyslipidemia, pancreatitis risk prediction) while the industry side remains anchored by Arrowhead's positive plozasiran Phase 3 data, with the full readout due at ESC on August 30.

A quiet cycle on both fronts — the only qualifying PubMed hit is a JAMA news synopsis recapping June's Tryngolza approval rather than new primary research, and no fresh trade-press stories on SHTG, Arrowhead, Alnylam, or Ionis cleared the 5-day/dedup bar, with the field's most consequential items (Arrowhead's SHASTA-3/4 topline and Alnylam's Amvuttra-driven selloff) already covered in a recent episode.

No new top-tier journal papers this cycle — the science side is quiet reviews and case reports on the APOC3/LPL axis — while on the industry side Arrowhead bought itself a priority review voucher to speed its plozasiran (Redemplo) filing in severe hypertriglyceridemia, sharpening its race against Ionis's newly-expanded Tryngolza.

A quiet cycle on both fronts — one non-top-tier observational paper on pancreatitis recurrence in hypertriglyceridemia, and no fresh industry news beyond what's already been covered (Arrowhead's SHASTA-3/4 phase 3 data and the Ionis/Alnylam earnings stories all fell in prior episodes' windows).

A genuinely quiet cycle — the only new lipid-biology paper worth flagging is a human physiology study nailing down how ANGPTL3 deficiency reshapes triglyceride-rich lipoprotein clearance, while the industry side produced no fresh, previously-uncovered news on Arrowhead, Alnylam, or Ionis in the last five days.

It was a quiet week for new top-tier SHTG/ANGPTL/APOC3/LPL science, but Alnylam's 30% stock plunge on a surprise Amvuttra guidance cut is a reminder of how quickly sentiment can turn on RNAi-platform companies even as their lipid-focused programs (and rivals Ionis and Arrowhead) keep advancing on separate tracks.

It's a quiet cycle on both fronts — no new top-tier lipid papers cleared the bar, and the only notable industry item is a STAT News recap of the Arrowhead–Ionis triglyceride-drug rivalry that surfaces a previously undisclosed detail: Ionis's patent-infringement allegation against Arrowhead over the RNAi technology behind Redemplo (plozasiran).

A quiet cycle for new peer-reviewed lipid literature was overshadowed by Arrowhead Pharmaceuticals' Phase 3 plozasiran data in severe hypertriglyceridemia, which analysts are calling a "best-case scenario" that puts the drug on a collision course with Ionis's Tryngolza.

A quiet five days on both fronts — one dupe and one recycled news brief in the literature, and no fresh industry developments beyond the Tryngolza sHTG label expansion already covered last cycle.

It's a quiet cycle on both fronts — the only new PubMed entry is a review/perspective piece touching ANGPTL3 and apoC-III rather than primary data, and the industry side has nothing genuinely new since Tuesday's episode (Tryngolza's sHTG approval and related coverage were already covered in prior digests).

A quiet cycle on both fronts — Part A offers three next-tier papers on FCS-gene carrier states and the ANGPTL axis rather than any top-journal blockbuster, while Part B has no genuinely new news: the period's two biggest Ionis stories (the Tryngolza sHTG label expansion and the Wainua ATTR-CM trial failure) were both already covered in the July 10 episode and have no material updates since.

No top-tier journal papers cleared the bar this cycle so Part A drops down a tier to three directly relevant clinical items on hypertriglyceridemia and LPL biology, while Part B is dominated by a single but consequential Ionis story — the surprise Phase 3 failure of Wainua in ATTR-CM, which isn't a lipid-program readout but is reshaping the competitive and investor picture for Ionis and Alnylam.

A thin cycle on both sides — the only new top-tier hit is a review on residual lipid risk beyond LDL (ANGPTL/apoC-III/FGF21 pathways get a mention), and there's no fresh industry news in the last 5 days beyond last week's Tryngolza sHTG approval, which was already covered.

A quiet cycle overall — no top-tier journal papers on our core targets cleared the bar and no genuinely new industry news broke in the last five days, so this episode leans on two next-best-tier papers (an ANGPTL3-inhibitor phase 3 extension and a pediatric SHTG risk-prediction study) while the Arrowhead/Ionis/Alnylam news front stayed silent beyond what's already been covered.

A quiet science week surfaces a novel APOC3 role in diabetic retinal angiogenesis and a diagnostic yield study for monogenic HTG, while the industry story remains Ionis' Tryngolza commercial launch into the 3.6-million-patient sHTG market following last week's FDA approval.

The week's dominant story is the FDA's June 24 approval of Ionis' Tryngolza (olezarsen) as the first-ever treatment for severe hypertriglyceridemia with a pancreatitis risk reduction claim; on the science side, three next-best-tier papers examine plozasiran's pharmacology, ApoC3's biphasic role across the MASLD spectrum, and urinary ANGPTL3 as a novel biomarker for podocyte injury.

A fresh meta-analysis of 14 APOC3-inhibitor trials confirms 80% reduction in acute pancreatitis risk alongside a compelling indirect head-to-head of olezarsen versus volanesorsen in FCS, while the most important industry event this cycle is the looming June 30 FDA decision on Tryngolza for severe hypertriglyceridemia.

A quiet breaking-news cycle on paper, but the lipid field is coiled for impact — a landmark Ionis FDA decision on olezarsen for severe hypertriglyceridemia is 11 days out, and fresh science clarifies who among heterozygous FCS-gene carriers will need APOC3-targeted therapy; on the bench, a novel SPP2–LPL axis offers a new handle on triglyceride homeostasis.

A meta-analysis confirms olezarsen's strong efficacy across eight RCTs, a human kinetic study illuminates exactly how ANGPTL3 deficiency reshapes triglyceride-rich lipoprotein metabolism, and a JACC case report highlights the management challenges of severe HTG in pregnancy — while the industry stage is quiet mid-week but poised for major events: the FDA PDUFA date for Tryngolza in sHTG arrives June 30, and Arrowhead's SHASTA-3/4 phase 3 readout is expected this month.

A quiet cycle on both fronts — no new top-tier lipid papers cleared the bar (the one journal hit, a Lancet D&E retrospective, was already covered Tuesday), and no fresh trade-press stories landed in the 5-day window, leaving the competitive backdrop dominated by the countdown to the FDA's June 30 decision on olezarsen in severe hypertriglyceridemia.

A sweeping 25-year review of lipid medicine published today in *Lancet Diabetes & Endocrinology* maps the journey from statins to RNA/DNA-targeted therapies for APOC3 and ANGPTL3; on the industry side, it's a quiet news week, but the Ionis FDA clock for Tryngolza in severe hypertriglyceridemia is now ticking down to a June 30 decision.

Circulation Research publishes a landmark trio of review articles on triglyceride-rich lipoprotein biology and RNA-targeted therapies today, while on the industry side it is a quiet week — but the Ionis Tryngolza FDA decision in sHTG is now just 25 days away and Arrowhead's SHASTA-3/4 phase 3 readouts are imminent.

A PNAS study reveals GPIHBP1 on brain oligodendrocytes as a novel docking site for LPL in the CNS, while an updated meta-analysis consolidates olezarsen's case as a potent APOC3-targeting therapy; on the industry side, a quiet week ahead of Ionis' looming June 30 FDA decision for Tryngolza in sHTG.

A quiet week on top-tier journal lipid papers, but four solid next-tier publications span plozasiran's approval story, a machine-learning breakthrough for predicting which HTG patients will develop pancreatitis, lipidomic signatures of drug-refractory HTG, and pediatric monogenic HTG genetics; on the industry side, Ionis's platform scores a landmark hepatitis B win this week, keeping the ASO powerhouse in the spotlight while its Tryngolza sHTG approval decision looms by June 30.

A landmark Circulation imaging trial finds that olezarsen's dramatic triglyceride lowering does not translate into coronary plaque regression at 12 months—raising fundamental questions about TG-lowering as an atherosclerosis therapy just as the 2026 ACC/AHA dyslipidemia guideline reframes how we should think about hypertriglyceridemia, and with Ionis's PDUFA date for the SHTG indication just five weeks away.

A landmark ACC/AHA dyslipidemia guideline dropped this week alongside a pivotal Circulation imaging trial showing olezarsen's dramatic triglyceride reduction does not translate into coronary plaque regression — a sobering finding that reframes what APOC3 inhibition can and cannot achieve at 12 months; on the industry side, the two biggest near-term catalysts remain Ionis' June 30 PDUFA date for olezarsen in sHTG and Arrowhead's expected EU approval of REDEMPLO, both just outside this cycle's lookback window but essential context.

A landmark Circulation imaging trial shows olezarsen dramatically lowers triglycerides but does not shrink coronary plaque, while two new meta-analyses confirm robust TG and pancreatitis benefits across the ApoC-III inhibitor class, and on the industry side both Arrowhead and Ionis are sprinting toward a mid-2026 collision in the sHTG market.

A quiet top-tier journal week — no NEJM/Lancet/JAMA hits, but the next tier delivered three substantial APOC3-inhibitor meta-analyses (olezarsen, plozasiran, and the full ApoC-III class) all landing the same message: large triglyceride drops and a dramatic ~80% cut in acute pancreatitis risk, plus a new HNF4A–SPP2–LPL axis that could expand the SHTG target list; the industry side was equally subdued, dominated by Madrigal's $1B-biobucks pickup of an Arrowhead RNAi MASH asset and the run-up to Ionis' Tryngolza sHTG PDUFA at the end of June.

A thin top-tier journal week pushed Part A to the next-best tier, where ApoC-III inhibitors keep stacking up favorable meta-analytic evidence and a new HNF4A–SPP2–LPL axis hints at fresh small-molecule entry points; the industry side is also quiet — the dominant story over the past seven days remains the run-up to the late-June Tryngolza sHTG PDUFA, with no major company-specific lipid news from the allowed outlets.

No top-tier journal acromegaly-style hits this cycle, but the broader lipid literature delivered two useful APOC3-inhibitor / olezarsen meta-analyses and a timely RNAi-for-lipid-disorders review; Part B was a quiet news week for Arrowhead, Alnylam, and Ionis specifically, with the Tryngolza severe-hypertriglyceridemia FDA decision (due by June 30) the dominant near-term catalyst.

No top-tier journal hits surfaced this week — showing the next-best tier — but the haul is unusually substantive: the first randomized evidence that an APOC3 siRNA (plozasiran) prevents recurrent pancreatitis in very severe hypertriglyceridemia, a major Hegele review repositioning ANGPTL3 as a remnant-cholesterol target, and new human data linking ANGPTL3/4/8 complexes to heart failure outcomes.

A genuinely consequential week — the 2026 ACC/AHA dyslipidemia guideline lands in Circulation and explicitly incorporates hypertriglyceridemia and Lp(a) management, while NEJM publishes a three-letter correspondence exchange that pressure-tests the CORE-TIMI 72 olezarsen pancreatitis data.

This week's top-tier literature is anchored by the new 2026 ACC/AHA Dyslipidemia Guideline — the most comprehensive update to U.S. lipid management in eight years — alongside a cluster of NEJM correspondence debating the landmark olezarsen APOC3-targeting RCT and its implications for pancreatitis prevention in severe hypertriglyceridemia.

A thin but consequential week — the new 2026 ACC/AHA multisociety dyslipidemia guideline lands in Circulation with hypertriglyceridemia and Lp(a) carved out as first-class targets, and three NEJM correspondence pieces continue the post-publication debate over olezarsen's pancreatitis benefit in severe hypertriglyceridemia.

A quiet week for new mechanistic and trial data, but two notable items: the 2026 ACC/AHA dyslipidemia guideline drops in Circulation (now formally folding hypertriglyceridemia into the same document as cholesterol), and three independent correspondence letters in NEJM probe the olezarsen pancreatitis-risk findings reported earlier this year by the TIMI group.

A thin original-research week, but two genuinely high-impact items: the new joint 2026 ACC/AHA dyslipidemia guideline (which now formally addresses hypertriglyceridemia and Lp(a) alongside LDL-C), and three published letters in NEJM debating the CORE-TIMI 72a/b olezarsen trial — including the Marston/Bergmark/Sabatine reply.

A thin but consequential week — the new 2026 ACC/AHA dyslipidemia guideline lands in *Circulation* and explicitly folds hypertriglyceridemia into the cholesterol-management framework, while *NEJM* publishes a correspondence cluster pressure-testing the pancreatitis-risk findings of the pivotal olezarsen (APOC3) trial.